Birdwatch Note
2024-10-16 01:08:08 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
William Makis lost his medical license years ago. His claims of treating patients with this treatment protocol are false. There is currently no scientific evidence to support Ivermectin use as a cancer treatment in humans, nor is it approved to treat cancer. https://apnews.com/article/fact-check-ivermectin-nih-cancer-cure-629592291079 https://jssbarristers.ca/rules/makis-v-college-of-physicians-and-surgeons-of-alberta-complaint-review-committee/
Written by 2A6B630D0AEA2ACC36E2189A989B042C8F44788D5C6526EF4EAC8856A79A73D8
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1846256384825848190
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1846357423315210352
- noteId - 1846357423315210352
- participantId -
- noteAuthorParticipantId - 2A6B630D0AEA2ACC36E2189A989B042C8F44788D5C6526EF4EAC8856A79A73D8
- createdAtMillis - 1729040888037
- tweetId - 1846256384825848190
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- William Makis lost his medical license years ago. His claims of treating patients with this treatment protocol are false. There is currently no scientific evidence to support Ivermectin use as a cancer treatment in humans, nor is it approved to treat cancer. https://apnews.com/article/fact-check-ivermectin-nih-cancer-cure-629592291079 https://jssbarristers.ca/rules/makis-v-college-of-physicians-and-surgeons-of-alberta-complaint-review-committee/
Note Ratings
| rated at | rated by | |
| 2024-10-27 17:27:18 -0500 | Rating Details | |
| 2024-10-21 17:37:42 -0500 | Rating Details | |
| 2024-10-17 01:44:40 -0500 | Rating Details | |
| 2024-10-16 23:27:59 -0500 | Rating Details | |
| 2024-10-16 18:55:41 -0500 | Rating Details | |
| 2024-10-16 15:59:24 -0500 | Rating Details | |
| 2024-10-16 13:42:14 -0500 | Rating Details | |
| 2024-10-16 12:59:40 -0500 | Rating Details | |
| 2024-10-16 12:54:19 -0500 | Rating Details | |
| 2024-10-16 12:47:42 -0500 | Rating Details | |
| 2024-10-16 12:25:55 -0500 | Rating Details | |
| 2024-10-16 11:33:39 -0500 | Rating Details | |
| 2024-10-16 11:07:26 -0500 | Rating Details | |
| 2024-10-16 11:07:06 -0500 | Rating Details | |
| 2024-10-16 10:17:44 -0500 | Rating Details | |
| 2024-10-16 10:12:06 -0500 | Rating Details | |
| 2024-10-16 09:48:43 -0500 | Rating Details | |
| 2024-10-16 09:16:20 -0500 | Rating Details | |
| 2024-10-16 08:12:33 -0500 | Rating Details | |
| 2024-10-16 07:46:12 -0500 | Rating Details | |
| 2024-10-16 07:19:41 -0500 | Rating Details | |
| 2024-10-16 04:41:10 -0500 | Rating Details | |
| 2024-10-16 02:15:44 -0500 | Rating Details | |
| 2024-10-16 00:52:07 -0500 | Rating Details | |
| 2024-10-16 00:27:57 -0500 | Rating Details | |
| 2024-10-16 00:07:30 -0500 | Rating Details | |
| 2024-10-15 23:43:45 -0500 | Rating Details | |
| 2024-10-15 23:24:17 -0500 | Rating Details | |
| 2024-10-15 22:37:54 -0500 | Rating Details | |
| 2024-10-15 21:11:18 -0500 | Rating Details | |
| 2024-10-15 21:05:13 -0500 | Rating Details | |
| 2024-10-15 20:56:07 -0500 | Rating Details | |
| 2024-10-17 10:20:07 -0500 | Rating Details | |
| 2024-10-17 03:53:30 -0500 | Rating Details | |
| 2024-10-16 18:38:28 -0500 | Rating Details | |
| 2024-10-16 16:36:14 -0500 | Rating Details | |
| 2024-10-16 14:16:15 -0500 | Rating Details | |
| 2024-10-16 13:33:15 -0500 | Rating Details | |
| 2024-10-16 12:38:49 -0500 | Rating Details | |
| 2024-10-16 11:48:18 -0500 | Rating Details | |
| 2024-10-16 11:42:12 -0500 | Rating Details | |
| 2024-10-16 11:04:51 -0500 | Rating Details | |
| 2024-10-16 10:47:46 -0500 | Rating Details | |
| 2024-10-16 10:39:54 -0500 | Rating Details | |
| 2024-10-16 10:36:36 -0500 | Rating Details | |
| 2024-10-16 10:27:44 -0500 | Rating Details | |
| 2024-10-16 10:27:37 -0500 | Rating Details | |
| 2024-10-16 10:19:34 -0500 | Rating Details | |
| 2024-10-16 10:04:12 -0500 | Rating Details | |
| 2024-10-16 10:00:52 -0500 | Rating Details | |
| 2024-10-16 09:25:12 -0500 | Rating Details | |
| 2024-10-16 09:15:29 -0500 | Rating Details | |
| 2024-10-16 08:21:51 -0500 | Rating Details | |
| 2024-10-16 08:09:26 -0500 | Rating Details | |
| 2024-10-16 07:55:16 -0500 | Rating Details | |
| 2024-10-16 05:01:41 -0500 | Rating Details | |
| 2024-10-16 04:09:47 -0500 | Rating Details | |
| 2024-10-16 02:27:23 -0500 | Rating Details | |
| 2024-10-15 23:22:43 -0500 | Rating Details | |
| 2024-10-15 23:15:01 -0500 | Rating Details | |
| 2024-10-15 22:59:01 -0500 | Rating Details | |
| 2024-10-15 20:52:47 -0500 | Rating Details | |
| 2024-10-15 20:32:05 -0500 | Rating Details | |
| 2024-10-22 03:23:07 -0500 | Rating Details | |
| 2024-10-17 17:07:54 -0500 | Rating Details | |
| 2024-10-17 06:05:59 -0500 | Rating Details | |
| 2024-10-16 17:25:55 -0500 | Rating Details | |
| 2024-10-16 15:42:42 -0500 | Rating Details | |
| 2024-10-16 14:58:33 -0500 | Rating Details | |
| 2024-10-16 14:35:34 -0500 | Rating Details | |
| 2024-10-16 13:16:43 -0500 | Rating Details | |
| 2024-10-16 12:05:13 -0500 | Rating Details | |
| 2024-10-16 11:12:48 -0500 | Rating Details | |
| 2024-10-16 10:50:09 -0500 | Rating Details | |
| 2024-10-16 10:44:36 -0500 | Rating Details | |
| 2024-10-16 10:22:02 -0500 | Rating Details | |
| 2024-10-16 10:18:12 -0500 | Rating Details | |
| 2024-10-16 10:10:34 -0500 | Rating Details | |
| 2024-10-16 10:09:42 -0500 | Rating Details | |
| 2024-10-16 09:18:19 -0500 | Rating Details | |
| 2024-10-16 08:49:31 -0500 | Rating Details | |
| 2024-10-16 08:07:14 -0500 | Rating Details | |
| 2024-10-16 07:28:24 -0500 | Rating Details | |
| 2024-10-16 07:02:22 -0500 | Rating Details | |
| 2024-10-16 03:52:51 -0500 | Rating Details | |
| 2024-10-16 03:33:45 -0500 | Rating Details | |
| 2024-10-16 02:02:41 -0500 | Rating Details | |
| 2024-10-16 01:37:08 -0500 | Rating Details | |
| 2024-10-16 01:36:30 -0500 | Rating Details | |
| 2024-10-15 21:42:06 -0500 | Rating Details | |
| 2024-11-07 07:15:45 -0600 | Rating Details | |
| 2024-11-06 20:52:03 -0600 | Rating Details | |
| 2024-10-17 08:03:13 -0500 | Rating Details | |
| 2024-10-17 06:59:19 -0500 | Rating Details | |
| 2024-10-17 01:14:06 -0500 | Rating Details | |
| 2024-10-16 23:57:00 -0500 | Rating Details | |
| 2024-10-16 22:26:04 -0500 | Rating Details | |
| 2024-10-16 21:50:41 -0500 | Rating Details | |
| 2024-10-16 14:22:47 -0500 | Rating Details | |
| 2024-10-16 13:35:21 -0500 | Rating Details | |
| 2024-10-16 12:49:46 -0500 | Rating Details | |
| 2024-10-16 12:42:53 -0500 | Rating Details | |
| 2024-10-16 12:01:20 -0500 | Rating Details | |
| 2024-10-16 11:27:40 -0500 | Rating Details | |
| 2024-10-16 10:46:43 -0500 | Rating Details | |
| 2024-10-16 10:41:24 -0500 | Rating Details | |
| 2024-10-16 10:11:49 -0500 | Rating Details | |
| 2024-10-16 07:24:29 -0500 | Rating Details | |
| 2024-10-16 06:13:40 -0500 | Rating Details | |
| 2024-10-16 05:31:28 -0500 | Rating Details | |
| 2024-10-16 03:22:56 -0500 | Rating Details | |
| 2024-10-16 00:23:07 -0500 | Rating Details | |
| 2024-10-15 21:03:04 -0500 | Rating Details | |
| 2024-10-15 20:45:43 -0500 | Rating Details | |
| 2024-10-15 20:09:57 -0500 | Rating Details | |
| 2024-11-12 11:51:31 -0600 | Rating Details | |
| 2024-10-22 01:43:37 -0500 | Rating Details | |
| 2024-10-17 05:15:06 -0500 | Rating Details | |
| 2024-10-16 21:22:22 -0500 | Rating Details | |
| 2024-10-16 15:24:23 -0500 | Rating Details | |
| 2024-10-16 15:09:26 -0500 | Rating Details | |
| 2024-10-16 15:02:07 -0500 | Rating Details | |
| 2024-10-16 14:49:03 -0500 | Rating Details | |
| 2024-10-16 13:35:35 -0500 | Rating Details | |
| 2024-10-16 12:58:03 -0500 | Rating Details | |
| 2024-10-16 12:04:33 -0500 | Rating Details | |
| 2024-10-16 11:43:20 -0500 | Rating Details | |
| 2024-10-16 08:37:00 -0500 | Rating Details | |
| 2024-10-16 07:28:50 -0500 | Rating Details | |
| 2024-10-16 05:51:05 -0500 | Rating Details | |
| 2024-10-16 00:45:34 -0500 | Rating Details | |
| 2024-10-16 00:45:18 -0500 | Rating Details | |
| 2024-10-15 23:00:25 -0500 | Rating Details | |
| 2024-10-15 22:06:38 -0500 | Rating Details | |
| 2024-10-15 21:12:36 -0500 | Rating Details | |
| 2024-10-15 20:30:29 -0500 | Rating Details |